Jobs
-
The 34th iteration of the Drug Delivery to the Lungs (DDL) Conference, DDL 2023, drew approximately 930 OINDP specialists to the Edinburgh International Conference Centre (EICC) December 6 – 8, with more than 100 additional… Read more . . .
-
Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed’s Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where… Read more . . .
-
Agomab Therapeutics announced that it has initiated a Phase 1 trial of its AGMB-447 inhaled ALK5 inhibitor that is expected to enroll 76 healthy subjects and idiopathic pulmonary fibrosis (IPF) patients. According to Agomab, the… Read more . . .
-
Irish start-up MDI Plus has announced the availability of its novel metered dose inhaler carton, which can be used as a spacer. The carton/spacer includes holes in each end of the cardboard box, with an… Read more . . .
-
CRO Oz-UK has announced that it is installing a new manufacturing line for metered dose inhalers that use LGWP propellants and expects the new line to be in operation by July 2024. According to the… Read more . . .
-
Aptar Pharma has announced the official opening of its new 7,000 sq m manufacturing facility in Mumbai, India. Aptar has been manufacturing MDI valves and pumps at the site since 2012. According to Aptar, the… Read more . . .
-
The FDA has extended the review period for Optinose’s sNDA seeking approval of Xhance fluticasone propionate nasal spray for the treatment of chronic sinusitis in patients without nasal polyps, Optinose said. Xhance was originally approved… Read more . . .
-
CDMO Recipharm announced that it has hired former Koura Global Business Development Director Simon Gardner as Business Development Specialist for pMDIs to assist customers with the transition to LGWP propellants. Recipharm President, Advanced Delivery Systems, Chris Hirst… Read more . . .
-
Nasus Pharma said that in a second PK study of FMXIN002 intranasal dry powder epinephrine, 91% of subjects who received a 4 mg dose of the nasal formulation reached the clinical threshold for plasma exposure… Read more . . .
-
Kindeva Drug Delivery and Koura Global parent company Orbia Advance Corporation announced that they have partnered to convert a currently marketed metered dose inhaler to use Koura’s HFA 152a (Zephex 152a), a lower global warming potential… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA